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To develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the
investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment.
Methods
To illustrate its research-enabling purpose, epidemiologic patterns and disease phenotypes were assessed among enrolled
subjects, including age at disease onset, annualized relapse rate (ARR), and time between the first and second attacks.
Results
As of December 2017, the Collaborative International Research in Clinical and Longitudinal Experience Study
(CIRCLES) had enrolled more than 1,000 participants, of whom 77.5% of the NMOSD cases and 71.7% of the
controls continue in active follow-up. Consanguineous relatives of patients with NMOSD represented 43.6% of the
control cohort. Of the 599 active cases with complete data, 84% were female, and 76% were anti-AQP4 seropositive.
The majority were white/Caucasian (52.6%), whereas blacks/African Americans accounted for 23.5%, Hispanics/
Latinos 12.4%, and Asians accounted for 9.0%. The median age at disease onset was 38.4 years, with a median ARR of
0.5. Seropositive cases were older at disease onset, more likely to be black/African American or Hispanic/Latino, and
more likely to be female.
Conclusions
Collectively, the CIRCLES experience to date demonstrates this study to be a useful and readily accessible resource to
facilitate accelerating solutions for patients with NMOSD.
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Neuromyelitis optica spectrum disorder (NMOSD) repre-
sents a chronic, potentially debilitating and life-threatening
neuroinflammatory process primarily targeting the optic
nerves, spinal cord, and brain.1–4 The typical clinical course of
NMOSD is marked by multiple relapses resulting in cumu-
lative neurologic disabilities. These events are interspersed
with remissions from disease activity of variable duration.
Heightened awareness of the disease among health care
providers and the public and recent advances in diagnostic
precision have increased estimates of worldwide NMOSD
prevalence, reaching as high as 10 per 100,000 in some
populations.5–8 This projection translates to more than
15,000 patients with NMOSD in the United States, suggest-
ing that hundreds of thousands of cases exist worldwide.
NMOSDdisproportionately affects females (up to 7:1 female-
to-male ratio), with anti-aquaporin-4 (AQP4) antibody
(hereafter referred to as anti-AQP4) positive disease having
even greater propensity for women.9,10 Yet, many details re-
garding etiology, pathogenesis, risk factors, and demography
of NMOSD are in need of greater understanding.
Although case series and observational studies suggest benefit
from immunotherapy, to date no treatment of NMOSD has
been proven safe and effective in prospective, double-masked
and adequately powered clinical trials.11–13 Because of its
rarity, insufficient access to well-characterized patient cohorts
has historically hindered studies as has an absence of high-
fidelity preclinical models of human disease. Limitations in
carefully standardized, longitudinal clinical research tools
have also impeded investigation of NMOSD immunopatho-
genesis. However, 4 separate clinical trials have now reported
positive results evaluating 3 compounds (eculizumab, satra-
lizumab, and inebilizumab) in studies assessing efficacy in
delaying or preventing relapses in NMOSD.
The Guthy-Jackson Charitable Foundation (GJCF) initiated
an observational study of NMOSD in which patients and
comparative controls are enrolled and evaluated longitudi-
nally in a standardized manner. This study, known as Col-
laborative International Research in Clinical and Longitudinal
Experience Studies (CIRCLES) for NMOSD, was launched
in November 2013. In CIRCLES, participant clinical data,
demographic profiles, and biospecimens were collected at
geographically dispersed academic medical centers located
throughout North America (figure 1).
The design and performance of the CIRCLES study are
described here, along with initial data analysis illustrating
the utility of its database and biorepository to advance
scientific knowledge and clinical care in NMOSD. It is
anticipated that this study will accelerate greater un-
derstanding of NMOSD and in turn the development of
safe and effective therapies to benefit patients with





Participant enrollment is conducted in accordance with the
guidelines specified by the Office of Human Research Pro-
tections of the US Food and Drug Administration. A stan-
dardized protocol, manual of operations, patient study file
(PSF), and informed consent or assent documents were ap-
proved by the institutional review board of each participating
institution. Written and verbal consent or assent was obtained
before beginning study procedures. The protocol and PSF
were updated periodically.
Study goals and design
Design
CIRCLES is a prospective, multicenter, cross-sectional,
and longitudinal study enabling comparisons of NMOSD
cases and controls from which clinical data and bio-
specimens were collected using standardized methods.
These were collected from cases at 6-month intervals and
at least annually from control participants. When possible,
clinical data and biospecimens were obtained from cases
during or within 10 days following clinically confirmed
relapses.
Goals
Two primary goals of CIRCLES include the following: (1)
establish a cohort of patients with NMOSD and comparative
controls who are longitudinally assessed at standardized
intervals and (2) analyze acquired clinical data and biospeci-
mens, thus improving knowledge of NMOSD and the patient
experience.
Sites
Multiple study sites were established at academic institutions
throughout North America (figure 1), each led by a clinical
investigator/neurologist with expertise in NMOSD. Study sites
were selected based on the size/activity of their NMOSD
Glossary
AQP4 = aquaporin-4; ARR = annual relapse rate; CRC = Clinical Research Coordinator; EDSS = Expanded Disability Status
Scale; GJCF = The Guthy-Jackson Charitable Foundation; ICC = International Clinical Consortium; IQR = interquartile
range; MOG = myelin oligodendrocyte glycoprotein; NMOSD = neuromyelitis optica spectrum disorder; PSF = patient
study file.
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patient cohort and capability to collect data and biospecimens
in the protocol-defined manner. Biospecimens, pre-
dominantly peripheral blood constituents, are rapidly
transferred to a centralized commercial laboratory for pro-
cessing and archiving.
Cohorts
The study comprises 3 participant cohorts based on the
following inclusion criteria: (1) cases with clinically di-
agnosed NMOSD according to either the Wingerchuk
200614 or International Panel for NMOSD Diagnosis
201514 criteria and classified with respect to anti-AQP4
serostatus; (2) comparative disease controls (including
CNS autoimmune diseases [e.g., MS]; other autoimmune
diseases [e.g., systemic lupus erythematosus, Sjögren
syndrome, and type I diabetes mellitus]; chronic non-
autoimmune inflammatory or systemic conditions [e.g.,
cardiovascular disease and type 2 diabetes]); and (3)
healthy controls (i.e., those not carrying a chronic disease
diagnosis at enrollment). Controls included consanguin-
eous relatives and unrelated individuals (tables 1 and 2).
Enrollment is targeted to a 2:1 ratio of cases to controls
and is monitored centrally. Individuals (both cases and
controls) are excluded if the treating physician feels that
they are not appropriate for the study. Control participants
are not sex or age matched. Some comparative disease
controls are recruited from referral cohorts (e.g., MS).
Others are recruited through opportunity or convenience.
Sites are instructed to enroll control participants at a rate
of 50% MS and 50% from the other categories.
Intervals
After enrollment, NMOSD cases are evaluated clinically at
6-month intervals to provide an updated clinical history and
complete set of biospecimens. Control participants un-
dergo these same assessments at least annually. The panel
of biospecimens routinely collected is listed in supple-
mental table 1 (links.lww.com/NXI/A121). The protocol
allows collection of CSF and additional tissues (e.g., pla-
centa) as available from medically indicated care. Relapses




Individuals fulfilling inclusion criteria and absent exclusion
criteria are eligible for enrollment. Individuals weighing <17
kg are excluded from blood collections but may otherwise
participate.
Enrollment
Clinical research coordinators (CRCs) screen information
pertaining to inclusion and exclusion criteria. Individuals
receive study information through mail and/or social media
and, where institutional review board-approved, have the
Figure 1 Geographic location of CIRCLES clinical sites
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option to provide preliminary information telephonically
with consent obtained in advance of study participation.
At enrollment, a thorough review of medical records and
clinical examination is performed by the study neurologist.
A complete disease history and additional relevant study
data are collected during the initial interview (table e-3,
links.lww.com/NXI/A121). The majority of participants to
date have been enrolled coinciding with medically in-
dicated appointments; however, in some cases, enrollment




The CIRCLES PSF (table e-2, links.lww.com/NXI/A121)
is completed for each participant at enrollment and up-
dated at each follow-up study visit. The PSF data include
demographics, disease phenotype, treatment history, and
other relevant characteristics. Other than NMOSD disease
history, identical clinical data are collected as appropriate
from case and healthy control participants.
Data security
Data are entered into a web-accessible and password-secured
electronic data capture system. The CIRCLES study incor-
porates a query management system that executes nightly. An
email notification is generated for each site’s CRC identifying
any new discrepant data. A weekly reminder email is also
provided for remaining discrepant data. The system tracks
queries from generation to resolution. Data are curated for
quality, consistency, and completeness by the Data Co-
ordinating Center biostatistics group before archiving. Study
data are backed up hourly, and a full snapshot of the study is
archived nightly.
Table 1 Summary of case participant characteristics by serostatus
Overalla (N = 599)
NMO-IgG status
p ValueNegative (N = 139) Positive (N = 449)
Female 504 (84.1%) 102 (73.4%) 393 (87.5%) <0.001g
Participant primary ethnicity/race designation <0.001g
Asian 54 (9.0%) 17 (12.2%) 37 (8.2%)
Black or African American 141 (23.5%) 16 (11.5%) 125 (27.8%)
Hispanic or Latino 74 (12.4%) 13 (9.4%) 60 (13.4%)
White 315 (52.6%) 87 (62.6%) 218 (48.6%)
Other 15 (2.5%) 6 (4.3%) 9 (2.0%)
Not reported 0 (0%) 0 (0%) 0 (0%)
Age at consent 47.1 (36.0–57.2) 43.3 (29.8–52.3) 48.6 (37.7–59.1) <0.001h
Age at first episode onsetb 38.4 (28.9–50.6) 35.1 (25.8–46.4) 39.4 (29.9–52.5) 0.002h
Relapse/year from disease onset to most recent visitc 0.5 (0.3–0.8) 0.5 (0.3–0.9) 0.4 (0.3–0.8) 0.031h
Time (y) from first episode onset to enrollmentb 4.6 (1.5–10.1) 3.8 (1.4–7.0) 4.9 (1.5–11.0) 0.008h
Longitudinally extensive transverse myelitisd 396 (66.1%) 83 (59.7%) 305 (67.9%) 0.064g
Optic neuritisf 395 (65.9%) 102 (73.4%) 286 (63.7%) 0.038g
Brainstem syndromef 155 (25.9%) 40 (28.8%) 111 (24.7%) 0.346g
Focal transverse myelitise 143 (23.9%) 46 (33.1%) 94 (20.9%) 0.004g
Area postrema syndromef 88 (14.7%) 20 (14.4%) 66 (14.7%) 0.920g
Cerebral syndromef 74 (12.4%) 20 (14.4%) 53 (11.8%) 0.425g
Diencephalic syndromef 23 (3.8%) 7 (5.0%) 15 (3.3%) 0.360g
Abbreviation: NMO = neuromyelitis optica.
a Eleven case participants have undetermined serostatus.
b Age at first episode onset and time from first episode onset to enrollment not recorded on 6 participants.
c Relapses per year from disease onset to most recent visit not recorded on 32 participants because of insufficient follow-up or missing data.
d Longitudinally extensive transverse myelitis not recorded on 3 participants.
e Focal transverse myelitis not recorded on 4 participants.
f Optic neuritis, brainstem syndrome, area postrema syndrome, cerebral syndrome, and diencephalic syndrome not recorded on 2 participants.
g χ2 test of association.
h Wilcoxon rank-sum test.
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Biospecimen repository
Collection, processing, and storage
Biospecimens are collected according to standard operating
procedures at enrollment and follow-up visits. A panel of blood
specimens is obtained (table e-1, links.lww.com/NXI/A121)
by routine venipuncture by a certified phlebotomist at each
scheduled clinical visit. Biospecimens are transported by express
courier to a commercial laboratory for processing, systematic
labeling, and archiving within 24 hours of collection under cer-
tified storage conditions (liquid nitrogen for peripheral blood
mononuclear cells and −80°C for sera, plasma, RNA, andDNA).
Quality and serostatus
Biospecimens are routinely assessed for quality postprocess-
ing and before cryopreservation. Autoantibody serostatus is
determined by the respective study site based on reference
laboratory assay or review of the case record. For analytical
purposes, seropositivity is defined as having detected anti-
AQP4 at any point during the participant’s history.
Statistical analysis
Analytical range
The current report encompasses data sets obtained from 2013
through 2017. The CIRCLES study is ongoing.
Analytical methods
Descriptive statistics (medians or interquartile ranges [IQRs]
for numeric variables; counts and percentages for categorical
variables) were used to analyze data. Wilcoxon rank-sum tests
were used to assess relationships between age at disease onset,
annualized relapse rate (ARR) during enrollment in the study,
and time between the first and second attacks in relation to
other demographic characteristics in NMOSD cases. Rela-
tionships between serostatus and race, serostatus and sex, and
race and sex were examined using χ2 tests. All analyses were
performed in SAS 9.4 (Cary, NC).
Data availability
Access to data and biospecimens is provided to qualified
scholars in a peer-reviewed process. Applications are adjudi-
cated by a biorepository oversight committee elected from




As of December 2017, CIRCLES had enrolled 849 NMOSD
cases and 339 controls, of which 658 (77.5%) and 243
(71.7%), respectively, continue to participate. The percentage
of enrollees remaining active has increased over time. Of the
161 participants enrolled in 2013, 49.7% are still active. This
compares to 73.7% of those enrolled in 2014, 67.9% in 2015,
74.4% in 2016, and 90.8% in 2017. Inability to contact
accounted for most inactivity (74%), followed by withdraw of
consent (14%), no longer able to participate (9%), and death
(2%). Of all participants, 60.3%, 31.3%, and 8.4%were enrolled
Table 2 Summary of control participant characteristics by relatedness to NMOSD cases
Case blood relative (N = 123) Unrelated (N = 95) Total (N = 218)
Female 73 (59.3%) 71 (74.7%) 144 (66.1%)
Racea
Asian 9 (7.3%) 8 (8.4%) 17 (7.8%)
Black or African American 8 (6.5%) 13 (13.7%) 21 (9.6%)
Hispanic or Latino 20 (16.3%) 16 (16.8%) 36 (16.5%)
White 81 (65.9%) 56 (58.9%) 137 (62.8%)
Other 4 (3.3%) 2 (2.1%) 6 (2.8%)
Age at consent (y) 44.9 (34.2–53.9) 50.9 (38.9–58.3) 47.1 (35.9–56.2)
Comparative disease
MS 37 (30.1%) 0 (0.0%) 37 (17.0%)
CNS autoimmune disease other than MS 10 (8.1%) 0 (0.0%) 10 (4.6%)
Systemic autoimmune disease 5 (4.1%) 14 (14.7%) 19 (8.7%)
CNS disorder unrelated to an inflammatory disease 4 (3.3%) 1 (1.1%) 5 (2.3%)
Systemic chronic condition 3 (2.4%) 4 (4.2%) 7 (3.2%)
None of the above 69 (56.1%) 78 (82.1%) 147 (67.4%)
Abbreviation: NMOSD = neuromyelitis optica spectrum disorder.
a Race not recorded on 1 participant.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 5 | September 2019 5
at study sites, national patient day events, and regional patient
day events, respectively. In-clinic enrollees, compared with
national and regional patient day enrollees, were more likely to
remain active (89.7% vs 55.1% and 74.5%, respectively). The
size of the enrolled cohort varied among study sites, with the
largest site enrolling 286 (24.1%) of all participants and the
smallest enrolling 20 (1.7%). Among active NMOSD cases,
495 (75.2%) have undergone one or more follow-up visits with
biospecimen collection. Among active controls, 129 (53.1%)
had one or more follow-up visits and biospecimen collection.
The remainder of the analyses presented are based on these
active cases and control participants who have complete data as
of the end of the study period.
Cohort demographics and epidemiology
In the CIRCLES cohort, the female-to-male ratio was 5.3:1
among cases (tables 1 and 2). NMOSD cases self-identified as
white/Caucasian (52.6%), 23.5% black/African American,
12.4% Hispanic/Latino, 9.0% Asian, and 2.5% from all other
races/ethnicities. The overall median age at NMOSD onset
was 38.4 years (IQR 28.9–50.6 years), appears to be normally
distributed, and spans the range from 2.7 to 79.9 years (figure 2).
The median time between disease onset and time to study en-
rollment was 4.6 years (IQR 1.5–10.1 years). CIRCLES cases
experienced an ARR of 0.5 (IQR 0.3–0.9). One hundred thirty-
two cases appear to be monophasic. For cases with ≥2 clinically
documented NMOSD relapses (n = 207), the median time
between the first and second attacks was 0.8 years (9 months;
IQR 3.3–27.9). The most common relapse manifestations were
longitudinally extensive transverse myelitis (≥2 vertebral seg-
ments; 396, 66.1%) and optic neuritis (395, 65.9%). Brainstem
syndromes were identified in 155 (25.9%) cases, 143 (23.9%)
manifested focally confined transverse myelitis, 88 (14.7%) area
postrema syndrome (e.g., prolonged or intractable nausea/
vomiting or hiccups), 74 (12.4%) cerebral syndrome (cognitive
and/or sensory impairment, pain, bowel and/or bladder dys-
function, or limb weakness), and 23 (3.8%) diencephalic and/or
brainstem syndromes (facial numbness, hearing loss, dysphagia,
or dysarthria) (table 1).
Biospecimen repertoire
Of the active NMOSD cases, 193 (32.2%) provided a single
set of biospecimens; 2 longitudinal sets were collected from
151 (25.2%) cases, 3 sets from 107 (17.9%), and 4 or more
from 131 (21.9%). Of the active controls, 102 (46.8%) pro-
vided a single biospecimen set, 65 (29.8%) 2 sets, 26 (11.9%)
3 sets, and 21 individuals (9.6%) have provided 4 or more
longitudinal samples.
Correlation analyses
Bioinformatic analyses have revealed several significant cor-
relates in the CIRCLES cohort (table 1). Anti-AQP4 sero-
positive cases were more likely to be female (87.5%)
compared with seronegative cases (73.4%, p < 0.001). Sig-
nificant differences in racial distribution by serostatus (p <
0.001) were also detected. This result was driven largely by
differences in the black/African American and white race
categories. Although black/African American participants
accounted for only 11.5% of the seronegative population, they
comprise 27.8% of seropositive cases. Similarly, Hispanic/
Latino cases represent only 9.4% of seronegative cases, but
13.4% of seropositive cases. Conversely, white/Caucasian
cases account for 62.6% of seronegative cases, but less than
half (48.6%) of the seropositive cases. Similarly, Asians ac-
count for a higher percentage of the seronegative population
(12.2%) compared with the seropositive population (8.2%).
Overall, seropositive cases are older at initial NMOSD attack
compared with seronegative participants (39.4 vs 35.1; p =
0.002; figure 2). White/Caucasian and Asian cases tend to be
older at first attack compared with black/African Americans
or Hispanics (41.1 and 38.3 vs 36.5 and 36.0, p < 0.001;
table 3). Seropositive cases tend to have lower ARR than those
who are seronegative (0.46 vs 0.55; p = 0.030). No significant
differences were detected between race and ARR (p = 0.34).
Of the 218 control participants, 95 (43.6%) are consanguin-
eous with an enrolled case. One hundred forty-four (66.1%)
are female. The median age of controls at enrollment was 47.1
years. Of the related controls, none have MS, 17.9% have
another autoimmune disease, and 82.1% have no comparative
disease or chronic condition. Of the unrelated controls, 28.5%
haveMS, 15.4% have another autoimmune disease, and 56.1%
have no comparative disease or condition (table 2).
Discussion
The CIRCLES study represents a unique and multicenter
longitudinal observational study, which has successfully
recruited and retained a large number of patients affected by
the rare disease NMOSD. The substantial number of control
participants who are consanguineous with enrolled cases also
Figure 2 Age at onset by serostatus and gender
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provides important new opportunities to understand disease
resilience. In this respect, individuals with familial genotypes
and environmental exposures, but who do not manifest
NMOSD, can be evaluated in relation to patients with
NMOSD. In addition, the CIRCLES project reflects the
collaborative input of the GJCF-ICC, a global network of
scientific and medical experts in NMOSD.
The demographic characteristics of the CIRCLES cohort
to date are comparable to those of previously described
NMOSD registries.13,15–22 Interesting relationships have
emerged from initial demographic, epidemiologic, and cor-
relational analyses of this cohort. Key relationships include
identification of correlations between disease attributes and
sex, age, and race. NMOSD cases are predominantly female
(5.3:1) and anti-AQP4 seropositive (76.4%). Disease onset
most commonly occurs in the fourth decade of life. These
findings are congruent with recent epidemiologic studies
of NMOSD regarding sex predominance, age at onset, and
disease clustering in individuals and their first-degree
relatives.5,23–25
Analysis of the CIRCLES cohort supports the concept that
a sizable proportion of cases satisfying either 2006 or 2015
diagnostic criteria for NMOSD14,26 includes individuals in
whom anti-AQP4 is not detected. Approximately 20.6% of
female and 39.8% of male cases in CIRCLES are anti-AQP4
seronegative, representing a significant difference based on
sex (p < 0.001). Whether such proportions accurately reflect
anti-AQP4 serostatus worldwide, correlate with specific dis-
ease phenotypes, or inform regarding response to therapy
remains uncertain. Key among the proximate determinants of
this serostatus are anti-AQP4 assay sensitivities and specific-
ities. For example, it is possible that therapies inadvertently
affect selection bias (e.g., rituximab targeting B cells). How-
ever, no consistent evidence published to date has proven
these therapies alter antibody detection in Clinical Laboratory
Improvement Amendments–approved assays. Seropositive
cases are more likely to be female, and self-identified black/
African American or Hispanic/Latino patients are more likely
to be anti-AQP4 seropositive, congruent with earlier reports.5
Furthermore, cases in which anti-AQP4 is detected are older
at first attack than those who are seronegative (39.4 vs 35.1,
respectively, p = 0.002). Although white/Caucasian cases
accounted for nearly 63% of the anti-AQP4 seronegative co-
hort, they account for less than 50% of seropositive cases. The
age at first attack also differed by race, with a nearly 5-year
disparity between the median age at onset for Hispanics/
Latinos compared with white/Caucasians. This finding could
reflect socioeconomic skewing of access to specialized medi-
cal care, a difference in disease activity/severity, other fac-
tor(s), or a combination of factors.
Of note, the prevalence of NMOSD appears to differ in dis-
tinct geographic regions. For example, the current estimate of
NMOSD prevalence is 3.9 per 100,000 in Olmsted County,
Minnesota (USA),5 similar to that reported in Denmark
(4 per 100,00027). In contrast, the prevalence ranges from
0.72 per 100,000 in England,28 0.89 per 100,000 in Spain,7 and
0.9 per 100,000 in Japan6 to 1.96 per 100,000 in Wales,29
2.5 per 100,000 in the French West Indies,30 2.6 per 100,000
in India,31 and as high as 10 per 100,000 in Martinique.5 It is
possible that differences in diagnostic criteria could underlie
at least some of these apparent differences. In any event, the
current CIRCLES data offer insights extending those pro-
vided by recent reviews.8,32
The sizable proportion of cases in which anti-AQP4 is not
detected suggests that the NMOSD phenotype can result
from multiple, independent immunologic events. The
emerging recognition of individuals with phenotypes re-
sembling NMOSD, but in whom anti-myelin oligodendrocyte
glycoprotein (anti-MOG) autoantibodies are detected in the
absence of anti-AQP4,10,33,34 suggests at least 2 intriguing
possibilities: (1) a broader array of autoantigens than tradi-
tionally appreciated may contribute to astrocytopathies and/
or (2) patients having anti-MOG autoantibodies may reflect
a disease entity that is immunologically distinct from
NMOSD, despite largely superimposable clinical manifes-
tations. Thus, patients with anti-MOG antibodies may exhibit
disease features that are pathogenically distinct from
NMOSD, despite their similar clinical presentations.34,35
Table 3 Case demographic factors by race and ethnicity
N Female (N = 599) Age at onset (N = 593) ARR (N = 593)
White 315 253 (80.3%) 41.1 (31.1–53.0) 0.5 (0.3–0.9)
Black or African American 141 130 (92.2%) 36.5 (26.1–45.5) 0.5 (0.3–0.9)
Hispanic or Latino 74 67 (90.5%) 36.0 (22.6–46.5) 0.5 (0.3–1.0)
Asian 54 43 (79.6%) 38.3 (25.2–50.2) 0.4 (0.2–0.7)
Other 15 11 (73.3%) 31.7 (22.2–43.1) 0.5 (0.2–0.9)
p Value — 0.005a <0.001b 0.342b
Abbreviation: ARR = annualized relapse rate.
a χ2 test of association.
b Analysis of variance.
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Nevertheless, 1 recent epidemiologic study showed that
individuals with detectable anti-MOG antibody had similar
disease prevalence and long-term prognosis when compared
with patients lacking detectable anti-AQP4 or anti-MOG
antibody.10 Thus, the relationship between serology and
disease phenotype remains to be more clearly understood.
As with all large, multicenter clinical research studies, there
are limitations to CIRCLES. Some participants inconsistently
followed up or provided incomplete historical information.
Complete acquisition of PSF data elements, biospecimens, and
fully documented neurologic examination data has proven
challenging. In turn, acquiring disability data from incomplete
neurologic examinations has emerged as a high priority for
improvement. For example, although 90.9% of examinations
included completed motor function assessments, only 49.5%
assessed visual acuity, and 8.7% completed the Expanded
Disability Status Scale. The study has not systematically mon-
itored anti-MOG serostatus,16 as no approved clinical assay for
this autoantibody existed during the study period.
A unique aspect of CIRCLES concerns the detailed clinical
history captured at enrollment. For those whose disease is of
long duration, recall bias is possible. Beyond basic clinical
data, the CIRCLES PSF requests extensive retrospective
clinical information, including history of infectious diseases,
vaccinations, familial autoimmune diseases, medications,
and treatments. Although collection of such extensive in-
formation is labor intensive, the resulting data set enables
interrogations not possible from smaller or less compre-
hensive databases. Opportunities for enhancing study per-
formance are currently being addressed through refinements
of the study protocol. In particular, increased emphasis has
been placed on longitudinal participation, more frequent
site monitoring, and systematic methods for disseminating
information to study sites pertaining to study performance
and efficiency.
The design of CIRCLES allows direct comparisons between the
clinical courses of NMOSD and other autoimmune diseases,
informing key immunologic events unique to NMOSD. These
events in turn facilitate identification of clinically useful bio-
markers, including those heralding disease relapse, as well as novel
therapeutic targets, agents, and strategies. TheCIRCLES biobank
contains clinical information and biospecimens from ethnically
and geographically diverse cases, including those with heterotypic
phenotypes. Thus, CIRCLES represents a unique resource to the
academic and drug-discovery communities focused on finding
solutions for patients with NMOSD and may enhance parallel
efforts in other immune-based diseases.
In summary, areas of research urgently needed in NMOSD
include discovery of disease etiology, identification of risk
factors, and identification of biomarkers reflecting disease
activity and predicting relapse.36,37 The ongoing CIRCLES
continues to enroll and follow cases and categorical control
participants in a systematic and longitudinal manner. This
effort is intended to facilitate breakthroughs regarding the
epidemiology and pathogenesis of NMOSD, to reduce bar-
riers to performing well-designed therapeutic trials, and to
support postapproval studies of eventually approved thera-
peutics. Thus, the overarching goal of CIRCLES is to improve
patient quality of life through improved diagnosis, relapse
prevention, and eventual cures.38–40
The CIRCLES program enables unprecedented opportunities
to accelerate breakthroughs in scientific understanding and
clinical solutions for NMOSD. Key to the future applicability of
CIRCLES will be increased precision in diagnosis and unifor-
mity in the assessment and specification of distinct disease
phenotypes. These advances hinge on greater consistency of
serologic analysis regarding autoantibodies specific to disease
phenotype and standardization in the definition and severity
scoring of NMOSD relapses. As these advances are made, they
will be incorporated into the definitions used by CIRCLES,
attesting to the evolving nature of this research platform.
CIRCLES remains an open resource to facilitate hypothesis
generation and testing. Given the nature of the biospecimens
being collected, CIRCLES enables studies ranging from
genomics, transcriptomics, proteomics, and other molecular-
and cellular-based research, in addition to clinical investigation.
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